Knight Therapeutics Stock Price History
GUD Stock | CAD 5.77 0.02 0.35% |
Below is the normalized historical share price chart for Knight Therapeutics extending back to March 03, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Knight Therapeutics stands at 5.77, as last reported on the 30th of January, with the highest price reaching 5.79 and the lowest price hitting 5.71 during the day.
If you're considering investing in Knight Stock, it is important to understand the factors that can impact its price. As of now, Knight Stock is somewhat reliable. Knight Therapeutics has Sharpe Ratio of 0.028, which conveys that the firm had a 0.028 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Knight Therapeutics, which you can use to evaluate the volatility of the firm. Please verify Knight Therapeutics' Mean Deviation of 1.08, risk adjusted performance of 0.0382, and Downside Deviation of 2.44 to check out if the risk estimate we provide is consistent with the expected return of 0.0508%.
At this time, Knight Therapeutics' Common Stock Shares Outstanding is very stable compared to the past year. As of the 30th of January 2025, Common Stock is likely to grow to about 625 M, while Total Stockholder Equity is likely to drop about 823.4 M. . As of the 30th of January 2025, Price Earnings To Growth Ratio is likely to grow to 0.81, while Price To Sales Ratio is likely to drop 1.86. Knight Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Knight |
Sharpe Ratio = 0.028
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | GUD | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
1.82 actual daily | 16 84% of assets are more volatile |
Expected Return
0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Knight Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Knight Therapeutics by adding it to a well-diversified portfolio.
Knight Therapeutics Stock Price History Chart
There are several ways to analyze Knight Stock price data. The simplest method is using a basic Knight candlestick price chart, which shows Knight Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | January 30, 2025 | 5.77 |
Lowest Price | November 12, 2024 | 5.11 |
Knight Therapeutics January 30, 2025 Stock Price Synopsis
Various analyses of Knight Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Knight Stock. It can be used to describe the percentage change in the price of Knight Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Knight Stock.Knight Therapeutics Price Rate Of Daily Change | 1.00 | |
Knight Therapeutics Price Daily Balance Of Power | 0.25 | |
Knight Therapeutics Accumulation Distribution | 521.66 | |
Knight Therapeutics Price Action Indicator | 0.03 |
Knight Therapeutics January 30, 2025 Stock Price Analysis
Knight Stock Price History Data
The price series of Knight Therapeutics for the period between Fri, Nov 1, 2024 and Thu, Jan 30, 2025 has a statistical range of 0.64 with a coefficient of variation of 3.46. Under current investment horizon, the daily prices are spread out with arithmetic mean of 5.38. The median price for the last 90 days is 5.34.Open | High | Low | Close | Volume | ||
01/30/2025 | 5.71 | 5.79 | 5.71 | 5.77 | 37,755 | |
01/29/2025 | 5.78 | 5.78 | 5.71 | 5.75 | 93,220 | |
01/28/2025 | 5.70 | 5.76 | 5.69 | 5.75 | 71,372 | |
01/27/2025 | 5.69 | 5.71 | 5.65 | 5.70 | 36,785 | |
01/24/2025 | 5.55 | 5.71 | 5.55 | 5.71 | 42,123 | |
01/23/2025 | 5.58 | 5.67 | 5.57 | 5.67 | 45,577 | |
01/22/2025 | 5.52 | 5.64 | 5.52 | 5.61 | 85,580 | |
01/21/2025 | 5.52 | 5.57 | 5.50 | 5.57 | 46,067 | |
01/20/2025 | 5.50 | 5.57 | 5.50 | 5.57 | 64,126 | |
01/17/2025 | 5.41 | 5.49 | 5.38 | 5.48 | 71,818 | |
01/16/2025 | 5.34 | 5.46 | 5.30 | 5.40 | 106,883 | |
01/15/2025 | 5.28 | 5.32 | 5.26 | 5.29 | 57,805 | |
01/14/2025 | 5.29 | 5.31 | 5.25 | 5.30 | 46,425 | |
01/13/2025 | 5.32 | 5.35 | 5.26 | 5.29 | 46,426 | |
01/10/2025 | 5.39 | 5.42 | 5.31 | 5.34 | 53,734 | |
01/09/2025 | 5.43 | 5.49 | 5.41 | 5.49 | 50,097 | |
01/08/2025 | 5.37 | 5.43 | 5.37 | 5.42 | 85,112 | |
01/07/2025 | 5.42 | 5.47 | 5.38 | 5.41 | 51,945 | |
01/06/2025 | 5.37 | 5.45 | 5.37 | 5.42 | 69,933 | |
01/03/2025 | 5.35 | 5.41 | 5.35 | 5.37 | 22,129 | |
01/02/2025 | 5.31 | 5.41 | 5.31 | 5.34 | 53,500 | |
12/31/2024 | 5.25 | 5.34 | 5.25 | 5.34 | 53,480 | |
12/30/2024 | 5.33 | 5.33 | 5.25 | 5.25 | 40,538 | |
12/27/2024 | 5.25 | 5.36 | 5.25 | 5.34 | 91,918 | |
12/24/2024 | 5.25 | 5.33 | 5.23 | 5.25 | 39,953 | |
12/23/2024 | 5.16 | 5.26 | 5.15 | 5.23 | 61,869 | |
12/20/2024 | 5.11 | 5.20 | 5.11 | 5.19 | 82,031 | |
12/19/2024 | 5.23 | 5.23 | 5.11 | 5.16 | 105,330 | |
12/18/2024 | 5.23 | 5.26 | 5.19 | 5.21 | 57,684 | |
12/17/2024 | 5.18 | 5.22 | 5.15 | 5.22 | 52,685 | |
12/16/2024 | 5.17 | 5.20 | 5.15 | 5.18 | 108,303 | |
12/13/2024 | 5.15 | 5.23 | 5.13 | 5.20 | 66,445 | |
12/12/2024 | 5.30 | 5.30 | 5.15 | 5.15 | 107,624 | |
12/11/2024 | 5.32 | 5.32 | 5.25 | 5.28 | 68,423 | |
12/10/2024 | 5.30 | 5.36 | 5.30 | 5.33 | 37,882 | |
12/09/2024 | 5.35 | 5.39 | 5.33 | 5.36 | 43,564 | |
12/06/2024 | 5.34 | 5.37 | 5.30 | 5.33 | 58,896 | |
12/05/2024 | 5.35 | 5.39 | 5.33 | 5.34 | 30,859 | |
12/04/2024 | 5.37 | 5.40 | 5.30 | 5.36 | 85,500 | |
12/03/2024 | 5.35 | 5.45 | 5.31 | 5.39 | 141,189 | |
12/02/2024 | 5.24 | 5.34 | 5.24 | 5.34 | 105,304 | |
11/29/2024 | 5.23 | 5.30 | 5.23 | 5.27 | 41,113 | |
11/28/2024 | 5.22 | 5.29 | 5.22 | 5.22 | 27,931 | |
11/27/2024 | 5.25 | 5.31 | 5.24 | 5.27 | 63,468 | |
11/26/2024 | 5.27 | 5.34 | 5.22 | 5.29 | 169,346 | |
11/25/2024 | 5.37 | 5.54 | 5.27 | 5.27 | 2,099,013 | |
11/22/2024 | 5.27 | 5.32 | 5.25 | 5.29 | 84,117 | |
11/21/2024 | 5.20 | 5.30 | 5.20 | 5.30 | 97,140 | |
11/20/2024 | 5.15 | 5.21 | 5.15 | 5.21 | 96,265 | |
11/19/2024 | 5.27 | 5.32 | 5.15 | 5.15 | 108,458 | |
11/18/2024 | 5.21 | 5.40 | 5.21 | 5.37 | 102,247 | |
11/15/2024 | 5.25 | 5.25 | 5.15 | 5.19 | 103,432 | |
11/14/2024 | 5.14 | 5.22 | 5.14 | 5.22 | 70,952 | |
11/13/2024 | 5.12 | 5.16 | 5.09 | 5.15 | 115,063 | |
11/12/2024 | 5.18 | 5.21 | 5.09 | 5.11 | 372,614 | |
11/11/2024 | 5.20 | 5.24 | 5.12 | 5.17 | 148,502 | |
11/08/2024 | 5.15 | 5.28 | 5.10 | 5.26 | 205,700 | |
11/07/2024 | 5.70 | 5.70 | 5.13 | 5.15 | 489,416 | |
11/06/2024 | 5.70 | 5.82 | 5.69 | 5.74 | 80,888 | |
11/05/2024 | 5.66 | 5.75 | 5.65 | 5.73 | 33,406 | |
11/04/2024 | 5.74 | 5.76 | 5.65 | 5.65 | 31,400 |
About Knight Therapeutics Stock history
Knight Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Knight is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Knight Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Knight Therapeutics stock prices may prove useful in developing a viable investing in Knight Therapeutics
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 123.6 M | 123.8 M |
Knight Therapeutics Stock Technical Analysis
Knight Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
All Next | Launch Module |
Knight Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Knight Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Knight Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Knight to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.0382 | |||
Jensen Alpha | 0.1206 | |||
Total Risk Alpha | (0.1) | |||
Sortino Ratio | (0.01) | |||
Treynor Ratio | (0.07) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.